Stock GLPG GALAPAGOS NV
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Galapagos NV Stock Euronext Bruxelles

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Financials

Sales 2024 * 296M 323M Sales 2025 * 302M 329M Capitalization 1.65B 1.8B
Net income 2024 * -22M -23.99M Net income 2025 * -72M -78.52M EV / Sales 2024 * -5.8 x
Net cash position 2024 * 3.37B 3.67B Net cash position 2025 * 2.97B 3.24B EV / Sales 2025 * -4.38 x
P/E ratio 2024 *
-41.9 x
P/E ratio 2025 *
-15.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.64%
More Fundamentals * Assessed data

Chart Galapagos NV

Dynamic Chart

Latest news about Galapagos NV

Frontier Medicines Corporation announced that it has received $99.999997 million in funding from a group of investors CI
Galapagos Plans to Present 'Encouraging' Results for GLPG5101 in Non-Hodgkin Lymphoma MT
Galapagos NV Presents Encouraging New Data for CD19 CAR-T Candidate GLPG5101 in Non-Hodgkin Lymphoma at EHA 2024 CI
Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug MT
Galapagos and Adaptimmune Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-Cell Therapy Candidate, uza-cel CI
Galapagos Partners with Blood Centers of America to Decentralize CAR-T Cell Therapy Manufacture MT
Galapagos and Blood Centers of America Announce Strategic Collaboration to Accelerate Galapagos? Decentralized Car-T Manufacturing Network in the U.S CI
Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024
Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024 CI
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41 MT
Galapagos NV Announces Board Changes CI
Galapagos to Seek Acquisitions CI
More news

Latest transcript on Galapagos NV

Logo Galapagos NV
Galapagos NV, Q1 2024 Earnings Call, May 03, 2024
More transcripts

Analyst Recommendations on Galapagos NV

Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41 MT
JPMorgan Cuts Galapagos Price Target to $37 From $45, Maintains Neutral Rating MT
Morgan Stanley Adjusts Galapagos' Price Target to $40 From $42, Keeps Equalweight Rating MT
RBC Cuts Price Target on Galapagos to $38 From $41, Keeps Sector Perform Rating MT
More recommendations

Press releases Galapagos NV

Galapagos : Galapagos presents encouraging new data for CD19 CAR T candidate GLPG5101 in non Hodgkin lymphoma at EHA 2024 PU
Galapagos : presents encouraging new data for CD19 CAR T candidate GLPG5101 in non Hodgkin lymphoma at EHA 2024 PU
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 GL
Galapagos : Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T cell therapy candidate, uza cel, in head & neck cancer and potential future so PU
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications GL
More press releases

News in other languages on Galapagos NV

BelMid presteert beter dan CAC en AEX
Bemoedigende data Galapagos voor potentiele lymfeklierkankerbehandeling
Galapagos : presenteert bemoedigende nieuwe resultaten voor CD19 CAR T kandidaat GLPG5101 in non Hodgkin lymfoom op EHA 2024
Galapagos presenteert bemoedigende nieuwe resultaten voor CD19 CAR-T kandidaat GLPG5101 in non-Hodgkin lymfoom op EHA 2024
AVIS D'ANALYSTES DU JOUR : Safran, Saint-Gobain, Rémy Cointreau, Soitec, OVH, HelloFresh, Clariane...
More news

Managers and Directors - Galapagos NV

Managers TitleAgeSince
Paulus Stoffels CEO
 Chief Executive Officer 62 22-03-31
Thad Huston DFI
 Director of Finance/CFO 54 23-05-31
Sandra Cauwenberghs IRC
 Investor Relations Contact - 20-10-31
Members of the board TitleAgeSince
Andrew Dickinson BRD
 Director/Board Member 54 Mar. 26
Jérôme Contamine BRD
 Director/Board Member 66 22-04-25
Simon Sturge BRD
 Director/Board Member 65 23-09-18
More insiders

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Sector
Biotechnology & Medical Research
Calendar
2024-07-31 - Q2 2024 Earnings Release
Related indices
BEL-20
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+22.10% 46.55B
LONZA GROUP AG Stock Lonza Group AG
+46.45% 41.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.12% 40.84B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+36.10% 32.95B
CELLTRION, INC. Stock Celltrion, Inc.
-6.30% 28.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+18.71% 27.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+46.15% 14.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+44.52% 13.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.19% 12.18B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GLPG Stock
  4. GLPG Stock